Biotech ETF SBIO Can Get Its Groove Back

With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction. That pullback, though, may be a buying opportunity.

ETF Trends • Sep 29, 2026

SBIO: Promising Pipelines, Insufficient Return Potential

SBIO is rated Sell due to a significant overvaluation vs. its probability-weighted fair NAV of $37.86, far below the $62.22 market price. Current fund pricing capitalizes on large portions of future biotech success, exposing investors to downside if clinical or commercial outcomes disappoint. Despite credible late-stage pipelines and solid cash runways, dilution risk remains high, with modeled scenarios projecting negative annualized returns.

Seeking Alpha • Sep 25, 2026

SBIO: Big Pharma Needs What This Fund Owns

The ALPS Medical Breakthroughs ETF targets late-stage biotech firms primed for clinical catalysts and acquisition interest. SBIO's methodology requires at least one Phase II/III program and 24 months of cash, reducing dilution risk before key events. Recent acquisitions of top holdings post-August highlight SBIO's ability to capture M&A-driven upside and recycle capital into new prospects.

Seeking Alpha • Sep 22, 2026

SBIO ETF Rallies on Clinical Trial Wins & M&A Demand

The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside.  SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.

ETF Trends • Sep 16, 2026

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.

Zacks Investment Research • Sep 8, 2026

3 Small-Cap ETFs to Watch as Russell 2000 Hits Record

The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.

ETF Trends • Aug 17, 2026

Risk-Wary Family Offices Double Down on Infrastructure

Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.

ETF Trends • Jul 21, 2026

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

ETF Trends • Jul 13, 2026

SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn

ALPS Medical Breakthroughs ETF targets late-stage clinical trial biotechs primed for outsized performance and M&A. SBIO's selective criteria focus on U.S.-listed firms with strong cash positions, Phase 2/3 assets, and near-term catalysts, creating a portfolio of high-volatility, high-alpha 'lottery tickets.' SBIO has delivered 111% returns over the past year, outperforming the S&P 500; its holdings have seen notable buyouts and clinical milestones.

Seeking Alpha • Jul 7, 2026

Biotech Gives SBIO Its Best Month Since 2023

Biotech stocks delivered their best single month since late 2023 in June, carrying the ALPS Medical Breakthroughs ETF (SBIO) to one of the top returns across the ALPS lineup. Key Takeaways: SBIO returned 18.7% in June, its best single month since December 2023.

ETF Trends • Jul 2, 2026